BIOMAT Database Logo BIOMAT Database Logo

[Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy]. 2002

Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
First Department of Internal Medicine, Tokyo Medical University.

A 73-year-old woman with chronic myeloid leukemia was treated with interferon-alpha, hydroxyurea, and busulfan before imatinib mesylate treatment. The leukocyte count was 8,400/; hemoglobin concentration, 12.0 g/; and platelet count, 19.7 x 10(4)/. She received 400 mg of imatinib mesylate for 17 days before the agent was discontinued because of pancytopenia. A bone marrow biopsy on the 87th day after the last imatinib mesylate administration demonstrated severe hypocellularity. She needed many RBC and Plt transfusions and filgrastim administration. Grade 4 neutropenia continued for 35 days and Grade 3 thrombocytopenia continued for over 122 days. Imatinib mesylate, an agent targeting BCR-ABL, is expected to be useful as an effective therapeutic agent for chronic myeloid leukemia. However the present case suggests that its appropriate dose is individually variable and we should carefully consider the former treatment, and the clinical stage of the disease before initiating imatinib treatment.

UI MeSH Term Description Entries
D010198 Pancytopenia Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets. Pancytopenias
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068877 Imatinib Mesylate A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide,CGP 57148,CGP-57148,CGP57148B,Gleevec,Glivec,Imatinib,Imatinib Methanesulfonate,ST 1571,ST1571,STI 571,STI-571,STI571,CGP57148,Mesylate, Imatinib,Methanesulfonate, Imatinib
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001549 Benzamides BENZOIC ACID amides.
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
[Chronic myeloid leukemia and imatinib mesylate therapy].
January 2004, Vnitrni lekarstvi,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy.
June 2022, Clinical case reports,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Macular ischemia associated with imatinib mesylate therapy for chronic myeloid leukemia.
January 2009, Retinal cases & brief reports,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
February 2007, International journal of hematology,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
March 2009, Annals of hematology,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Imatinib mesylate in chronic myeloid leukemia.
September 2007, Current stem cell research & therapy,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Reduced dose imatinib mesylate therapy for chronic myeloid leukemia.
November 2004, Leukemia & lymphoma,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy.
March 2007, Clinical nephrology,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Treatment of chronic myeloid leukemia with imatinib mesylate.
June 2006, International journal of clinical oncology,
Masahiko Sumi, and Tetsuzo Tauchi, and Takashi Shimamoto, and Goro Sshida, and Akihiro Nakajima, and Yoshikazu Ito, and Kazuma Ohyashiki
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
February 2006, Haematologica,
Copied contents to your clipboard!